Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2026-01-03 @ 1:00 PM
Study NCT ID:
NCT04688151
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-22
First Post:
2020-12-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
Sponsor:
National Health Research Institutes, Taiwan
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
T2420
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None